Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
|
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
  • [41] Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist
    Nayak, Sunil U.
    Cicalese, Stephanie
    Tallarida, Chris
    Oliver, Chicora F.
    Rawls, Scott M.
    BRAIN BEHAVIOR AND IMMUNITY, 2020, 83 : 288 - 292
  • [42] CCR5 and CXCR4 antagonist and agonist binding sites
    Martin Teintze
    Royce Wilkinson
    Paul Grieco
    John Mills
    Edward Dratz
    Retrovirology, 3 (Suppl 1)
  • [43] CCR5 and CXCR4 antagonist and agonist binding sites
    Teintze, Martin
    Wilkinson, Royce
    Grieco, Paul
    Mills, John
    Dratz, Edward
    RETROVIROLOGY, 2006, 3
  • [44] Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis
    Amerzhanova, Yerkezhan
    Vangelista, Luca
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies
    Flynn, Jacqueline K.
    Roche, Michael
    Paukovics, Geza
    Salimi, Hamid
    Duncan, Renee C.
    Moore, Miranda S.
    Ellet, Anne
    Gray, Lachlan R.
    Jubb, Becky
    Westby, Mike
    Purcell, Damian F. J.
    Lewin, Sharon R.
    Lee, Benhur
    Payne, Richard J.
    Churchill, Melissa J.
    Gorry, Paul R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A212 - A212
  • [46] The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density
    Desmetz, Caroline
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Rabesandratana, Herisoa
    Clot, Jacques
    Corbeau, Pierre
    IMMUNOLOGY, 2006, 119 (04) : 551 - 561
  • [47] A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc
    Jacqmin, Philippe
    McFadyen, Lynn
    Wade, Janet R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 : 95 - 106
  • [48] The frequency of CCR5 promoter polymorphisms and CCR5 Δ 32 mutation in Iranian populations
    Zare-Bidaki, Mohammad
    Karimi-Googheri, Masoud
    Hassanshahi, Gholamhossein
    Zainodini, Nahid
    Arababadi, Mohammad Kazemi
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2015, 18 (04) : 312 - 316
  • [49] Drug evaluation: Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS
    Meanwell, Nicholas A.
    Kadow, John F.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (08) : 669 - 681
  • [50] Eotaxin: A CCR2 antagonist and a CCR5 agonist on human monocytes
    Ogilvie, P
    Bardi, G
    Loetscher, P
    Baggiolini, M
    Uguccioni, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 532 - 532